.svg)
The era of the weight-loss pill has officially arrived.
For years, getting meaningful GLP-1 support for weight management meant giving yourself a shot once a week and keeping injection pens or vials in the fridge. Considering how challenging weight loss can be, many felt the logistical downsides were worth it, but millions of others were hesitant to make self-administered injections a regular part of their lives.
In December 2025, the first GLP-1 pill, the Wegovy® pill (semaglutide), was FDA-approved for weight management. This was quickly followed by the FDA approval of Foundayo™ (orforglipron) in April 2026.
Two FDA-approved GLP-1 pills on the market is good news for both providers and patients. This guide breaks down exactly how these pills work, how they’re different, and who might be a better candidate for each.
What is the Wegovy pill?
The Wegovy pill is an oral form of semaglutide, the active ingredient in the injectable Wegovy (and Ozempic®), taken once a day. Manufactured by Novo Nordisk, it was the first oral GLP-1 receptor agonist approved for weight management in the United States.
How semaglutide works
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a hormone our bodies naturally produce after eating, GLP-1. By activating GLP-1 receptors in the brain and gut, it suppresses appetite, slows gastric emptying, and helps regulate blood sugar, all of which can help reduce caloric intake.
The oral version uses a special absorption enhancer called SNAC, which allows semaglutide, a peptide that would normally be broken down in the stomach, to survive digestion and enter the bloodstream.
Dosing and administration for the Wegovy pill
The Wegovy pill comes in 1.5 mg, 4 mg, 9 mg, and 25 mg doses, taken once a day. Patients start at the lowest dose and gradually ramp up to the highest dose they can tolerate (up to 25 mg). Because SNAC-dependent absorption only works in a narrow pH window, the pill must be taken under certain conditions:
- On an empty stomach (first thing in the morning for most people)
- With no more than 4 oz. of plain water
- Followed by a 30-minute wait before eating or drinking anything else
Why the fasting rule exists: Taking the pill on an empty stomach is a requirement, not a preference. SNAC works by temporarily buffering the stomach’s acidic environment, which allows semaglutide through the stomach wall intact. Even small amounts of food or drink raise stomach acid and disrupt that window, reducing how much of the drug actually makes it into your bloodstream.
How to make it work in real life: The strict fasting rule can be tricky for some patients. Most find that the easiest approach is to take the pill right after they wake up—before getting out of bed, even—and then use the 30-minute window to shower, get dressed, or work out. Others like to set an alarm to take it, and then go back to sleep for a while longer before starting their day. The best strategy is the one you can stick to every day.
Clinical trial results
The FDA approval was based on the Phase 3 OASIS 4 trial, a 64-week study of 307 adults with obesity or overweight (without diabetes). Key findings include:
- 16.6% average weight loss among participants who fully adhered to treatment, which included lifestyle adjustments (balanced diet and regular movement)
- 13.6% average weight loss among all participants
- 1 in 3 fully adherent patients achieved 20% or greater weight loss
An indirect treatment comparison with the OASIS 4 trial found that the pill is comparable to what was seen in trials of the injectable Wegovy when taken as prescribed. However, no independent head-to-head trial has been published to date.
Who can take the Wegovy pill
The Wegovy pill is approved for adults with obesity (BMI of 30 or higher) and adults with overweight (BMI of 27 or higher) who have at least one weight-related condition (i.e., high blood pressure, high cholesterol, type 2 diabetes, cardiovascular disease).
The Wegovy pill is also approved to help reduce the risk of heart attack, stroke, or cardiovascular death in adults with cardiovascular disease and obesity or overweight.
Other factors, like your medical history and health goals, will also be taken into account before a prescription is written.
Wegovy pill pricing
Without insurance, pricing starts at $149/month. Those who have insurance coverage for weight management can pay as little as $25/month with a Novo Nordisk savings card. (See the Wegovy pill vs. injection cost breakdown for more details.)
What is Foundayo?
Foundayo is a once-daily oral version of orforglipron, a GLP-1 receptor agonist made by Eli LIlly, the same company behind Zepbound® and Mounjaro®.
How it works
Like the Wegovy pill, Foundayo activates GLP-1 receptors to suppress appetite, slow digestion, and help regulate blood sugar. But it’s different in a very important way: Foundayo’s active ingredient, orforglipron, is a small-molecule, non-peptide compound and is far more stable and bioavailable when taken orally. This means that no special absorption enhancer like SNAC is needed, so the pill can be taken any time, with or without fasting.
Dosing and administration for Foundayo
Foundayo is taken once a day, with or without food or water. Dosage starts at 0.8 mg and gradually increases based on the patient’s response and tolerability, up to 17.2 mg.
The flexible dosing schedule is the drug’s main advantage. With no fasting windows or scheduled alarms, it fits more seamlessly into most people’s routines.
Important note for people using hormonal birth control: Foundayo can reduce the effectiveness of oral contraceptive pills, which could increase the risk of unintended pregnancy. Patients taking birth control should discuss adding a backup contraceptive method with their provider before starting Foundayo.
Clinical trial results
The primary Phase 3 trial supporting FDA approval was the ATTAIN-1 trial, a 72-week study of 3,127 adults with obesity (without diabetes). Key findings include:
- 12.4% average weight loss participants who fully adhered to treatment at the highest dose, which included lifestyle adjustments (balanced diet and regular movement)
- 11.1% average weight loss among all participants at the highest dose
Who can take Foundayo
Foundayo is FDA-approved for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 or higher) with at least one weight-related condition.
Foundayo pricing
Without insurance, pricing starts at $149/month for the lowest dose. Those who have insurance coverage for weight management can pay as little as $25/month with an Eli Lilly savings card. Higher doses are cheaper than comparable injectable options.
What the Wegovy pill and Foundayo have in common
Despite coming from different companies and formulated with different molecules, the Wegovy pill and Foundayo share a lot of basic similarities:
- GLP-1 receptor agonists that are FDA-approved for chronic weight management
- Taken once per day
- Don’t require refrigeration
- Pricing starts at $149/month (without insurance)
- Similar side effects, the most common including nausea, vomiting, diarrhea, and constipation.
Main differences between Foundayo and the Wegovy pill
Foundayo and the Wegovy pill are both designed to support weight management, but they differ in a few key ways:
- Active ingredient: Foundayo uses orforglipron and the Wegovy pill uses semaglutide, which are absorbed differently by the body.
- Dosing requirements: While both are once-daily pills, the Wegovy pill has a lot more rules. It must be taken on an empty stomach with no more than 4 oz. of water, followed by a 30-minute wait before eating or drinking. Foundayo, on the other hand, can be taken any time of day, with or without food.
- Efficacy: Early trials suggest that the Wegovy pill may produce slightly more weight loss than Foundayo. However, no head-to-head study has been done yet, which will be the best way to determine which is more effective.
The most important difference between the two pills is user experience. They fit into your routine differently, which can affect how likely you are to take the medication consistently. The dosing schedule that is easiest to maintain should be part of your provider consultation.
Who should NOT take GLP-1 pills
The Wegovy pill and Foundayo both come with contraindications and are not recommended for everyone.
You should not take either pill if:
- You have a personal or family history of medullary thyroid carcinoma; both carry a boxed warning for thyroid C-cell tumors
- You have MEN 2
Use with extra caution or discuss carefully with your provider if you have a history of:
- Pancreatitis
- Gallbladder disease
- Kidney disease
- Diabetic retinopathy
- Eating disorders
- Significant reflux or gastroparesis
If you are pregnant or nursing, neither drug is recommended. Always tell your provider about all medications you’re taking (including contraceptives) and your medical history before starting a GLP-1 prescription in any form.
Switching from GLP-1 injectables to pills: What to know
Many people are already on injectable GLP-1 drugs and want to switch to the pill version, whether it’s part of a strategy to taper off injections, lower costs, or is more convenient for the person’s lifestyle.
Switching between the two is possible, but must be done under the direction of your provider. The dosing between the two drug types is different, for starters, and GI side effects may resurface during transition. Your provider will make sure you’re not overlapping two GLP-1 medications to help ensure a safe transition.
How to get a prescription for the Wegovy pill or Foundayo online
For many, the big question isn’t which pill to use, but how to get it. You can get a prescription from a licensed provider at your local medical practice or through a licensed telehealth platform.
If you decide to go the online route—which is what most people do if they don’t have insurance coverage—you have a few options. First is directly through the manufacturer’s website—foundayo.lilly.com for Foundayo or novocare.com/pharmacy/wegovy.html for Wegovy. A prescription from a licensed provider is required before you can purchase through either portal.
Your other option is to get a prescription through a telehealth platform like Shed. If you qualify for treatment, these companies allow you to purchase name-brand, FDA-approved GLP-1 medications through a membership program (which costs extra), and the medication is shipped straight to your door. The Shed Membership includes unlimited provider visits, complimentary text-based Health Coaching* for ongoing guidance, educational resources, dedicated support on prescription orders, and more.
Visit tryshed.com to see if you qualify for a Foundayo or Wegovy pill prescription.
Frequently asked questions
Are the Wegovy pill and Foundayo the same thing?
No. They contain different active ingredients (semaglutide vs. orforglipron), work through slightly different mechanisms at the molecular level, and have different dosing requirements. They are both oral GLP-1 pills FDA-approved for weight loss, but are different drugs.
Which pill causes more weight loss?
There is no head-to-head trial comparing the two, so direct comparison is limited. Individual results vary significantly.
Which GLP-1 pill is easier to take?
For many, Foundayo is the easier option. The Wegovy pill requires a strict fasting protocol, while Foundayo can be taken with or without food or drink.
Does either pill require refrigeration?
No. Neither pill requires refrigeration, which is one of the advantages over injectable GLP-1 drugs like Wegovy and Zepbound.
Can I switch from an injectable GLP-1 to Foundayo or the Wegovy pill?
Yes, under supervision from your provider. Individual experience varies and you may not see the same results after you switch.
Will I regain weight if I stop taking Foundayo or the Wegovy pill?
Most likely. Research on injectable GLP-1s shows patients regain roughly two-thirds of lost weight within a year of stopping. These pills are meant to treat chronic conditions and are not short-term treatments.
What are the side effects of GLP-1 pills?
Both the Wegovy pill and Foundayo share common GLP-1 side effects, which include nausea, vomiting, diarrhea, constipation, and stomach discomfort. Side effects tend to be most pronounced at the start of treatment and after dose increases, decreasing over time as the body adjusts.
References
OASIS 4 Trial — Primary Publication Wharton S, Lingvay I, Bogdanski P, et al.; OASIS 4 Study Group. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–1087. Doi :10.1056/NEJMoa2500969
Injectable Wegovy Comparability — Indirect Treatment Comparison Wharton S, Lingvay I, Bogdanski P, et al. (OASIS 4 Study Group). Summary and ACC Journal Scan: Oral Semaglutide Shows Weight Loss Comparable With High-Dose, SC Versions. American College of Cardiology. September 24, 2025. acc.org/latest-in-cardiology/journal-scans/2025/09/24/16/40/oasis-4.
ATTAIN-1 Trial — Primary Publication Wharton S, Aronne LJ, Stefanski A, et al.; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796–1806. Doi: 10.1056/NEJMoa2511774
Weight Regain After Stopping Semaglutide — STEP 1 Extension Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. Doi: 10.1111/dom.14725. PMC full text (open access): pmc.ncbi.nlm.nih.gov/articles/PMC9542252
Switching From Injectables to Foundayo — ATTAIN-MAINTAIN Trial Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial. Eli Lilly and Company. News release. December 18, 2025. investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after ClinicalTrials.gov: NCT06584916
This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting or changing any medication.
*Free text-based coaching may include automated responses generated by an AI assistant. All communication is monitored and reviewed by a licensed coach for accuracy, safety, and quality of support. AI does not replace professional medical or mental health advice.
Zepbound® (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Results vary by individual and are not guaranteed. Weight loss depends on factors such as diet, exercise, adherence, medical history, and individual response.
Zepbound® is a registered trademark of Eli Lilly and Company. Shed is not affiliated with or endorsed by Eli Lilly and Company.
Wegovy® (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Results vary by individual and are not guaranteed. Weight loss depends on factors such as diet, exercise, adherence, medical history, and individual response.
Wegovy® is a registered trademark of Novo Nordisk. Shed is not affiliated with or endorsed by Novo Nordisk.
Shed is not a pharmacy and does not dispense medications. Prescriptions are fulfilled and shipped by a third-party pharmacy. Medications carry risks and side effects. Patients should review the full prescribing information and discuss risks with their provider.
